Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 1.00 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 1.00 |
| ▸ | PTGES | O14684 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | DLAT | P10515 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 12/20 | 0.62 |
| ▸ | POLL | Q9UGP5 | 2/20 | 0.45 |
| ▸ | STAT1 | P42224 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15694978 | 1.00 | SIRT2 (1.00) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL15557965 | 1.00 | SIRT2 (1.00) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL14837010 | 1.00 | SIRT2 (1.00) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| Phloroglucinol SCHEMBL30222061 | 0.96 | SIRT2 (0.92) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL14233249 | 0.93 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL15694967 | 0.93 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL21907266 | 0.93 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL14577497 | 0.93 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL12634392 | 0.93 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL98723 | 0.93 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250269337-A1 | FLUID MIXING SYSTEMS AND METHODS | Life Technologies Corporation | 2025-08-28 | — | — | US | disclosed |
| CN-117230502-B | Surface treatment process for improving condensate water testing performance of metal part | 科文特亚环保电镀技术（江苏）有限公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4070869-B1 | METHOD OF ANALYZING A MONOMER OF A RECOMBINANT EXTRACELLULAR MATRIX PROTEIN BY SIZE EXCLUSION CHROMATOGRAPHY | HAPLNSCIENCE INC (KR) | 2024-01-31 | — | — | EP | disclosed |
| CN-117230502-A | Surface treatment process for improving condensate water testing performance of metal part | 科文特亚环保电镀技术（江苏）有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230295656-A1 | CELL CULTURE MEDIUM FOR USE IN PRODUCING GENE THERAPY PRODUCTS IN BIOREACTORS | VOYAGER THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230242959-A1 | MEDIUM COMPOSITION FOR CULTURING ANIMAL CELLS FOR PRODUCING RECOMBINANT EXTRACELLULAR MATRIX PROTEIN AND METHOD OF USING THE SAME | Haplnscience inc. (KR) | 2023-08-03 | — | — | US | disclosed |
| EP-4192514-A1 | CELL CULTURE MEDIUM FOR USE IN PRODUCING GENE THERAPY PRODUCTS IN BIOREACTORS | Voyager Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4070869-A1 | METHOD OF ANALYZING A MONOMER OF A RECOMBINANT EXTRACELLULAR MATRIX PROTEIN BY SIZE EXCLUSION CHROMATOGRAPHY | HAPLNSCIENCE INC. (KR) | 2022-10-12 | — | — | EP | disclosed |
| US-20220290201-A1 | MEDIUM COMPOSITION FOR CULTURING ANIMAL CELLS FOR PRODUCING RECOMBINANT EXTRACELLULAR MATRIX PROTEIN AND METHOD OF USING THE SAME | Haplnscience inc. (KR) | 2022-09-15 | — | — | US | disclosed |
| US-20220290182-A1 | CELL CULTURE MEDIUM FOR USE IN PRODUCING GENE THERAPY PRODUCTS IN BIOREACTORS | VOYAGER THERAPEUTICS, INC. | 2022-09-15 | — | — | US | disclosed |
| EP-4041863-A1 | MEDIUM COMPOSITION FOR CULTURING ANIMAL CELLS FOR PRODUCING RECOMBINANT EXTRACELLULAR MATRIX PROTEIN AND METHOD OF USING THE SAME | HAPLNSCIENCE INC. (KR) | 2022-08-17 | — | — | EP | disclosed |
| US-20220243225-A1 | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS | VOYAGER THERAPEUTICS, INC. | 2022-08-04 | — | — | US | disclosed |
| WO-2022146036-A1 | MEDIUM COMPOSITION FOR CULTURING ANIMAL CELLS FOR PRODUCING RECOMBINANT EXTRACELLULAR MATRIX PROTEIN AND METHOD OF USING THE SAME | Haplnscience inc. (KR) | 2022-07-07 | — | — | WO | disclosed |
| EP-4010465-A1 | CELL CULTURE MEDIUM FOR USE IN PRODUCING GENE THERAPY PRODUCTS IN BIOREACTORS | Voyager Therapeutics, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3962536-A1 | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICS) IN BIOREACTORS | Voyager Therapeutics, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20220064671-A1 | METHODS AND SYSTEMS FOR PRODUCING AAV PARTICLES | VOYAGER THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| WO-2022032153-A1 | CELL CULTURE MEDIUM FOR USE IN PRODUCING GENE THERAPY PRODUCTS IN BIOREACTORS | VOYAGER THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-9321713-B2 | Hyperforin analogs, methods of synthesis, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2000054785-A2 | STABILIZED BICYCLO[3.3.1]NONENES AND METHODS OF USE | SHAMAN PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000054760-A2 | BICYCLO (3.3.1) NONENES USEFUL FOR THE TREATMENT OF DIABETES AND HYPERTRIGLYCERIDEMIA | SHAMAN PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |